Dravet Syndrome Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies | GW Pharma, Zogenix Inc, Stoke Therapeutics, Takeda Pharma, Supernus Pharma

Posted on
by

Dravet Syndrome Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies | GW Pharma, Zogenix Inc, Stoke Therapeutics, Takeda Pharma, Supernus Pharma
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dravet Syndrome pipeline constitutes 12+ key companies continuously working towards developing 16+ Dravet Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Dravet Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Dravet Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dravet Syndrome Market.

 

Some of the key takeaways from the Dravet Syndrome Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Dravet Syndrome treatment therapies with a considerable amount of success over the years. 

  • Dravet Syndrome companies working in the treatment market are Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others, are developing therapies for the Dravet Syndrome treatment 

  • Emerging Dravet Syndrome therapies in the different phases of clinical trials are- TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others are expected to have a significant impact on the Dravet Syndrome market in the coming years.   

  • In June 2024, Two Phase III trials evaluating Takeda’s epilepsy medication soticlestat for patients with rare forms of epilepsy, including Lennox-Gastaut syndrome (LGS) and Dravet syndrome, did not achieve their primary objectives. Takeda conducted these studies under the names SKYLINE (NCT04940624) and SKYWAY (NCT04938427). Sarah Sheikh, Head of Takeda’s neuroscience unit, mentioned that the company will discuss its next actions regarding the drug with regulatory authorities.

  • In February 2024, The FDA has approved Encoded Therapeutics’ investigational new drug (IND) application for ETX101. This milestone permits Encoded to initiate clinical trials of the gene therapy candidate aimed at treating Dravet syndrome caused by SCN1A mutations. Furthermore, Australia’s TGA has granted approval under the Clinical Trial Approval (CTA) scheme to begin the trials.

  • In February 2024, Encoded Therapeutics has obtained approval from regulatory agencies in the U.S. and Australia to commence Phase 1/2 clinical trials evaluating ETX101, its gene therapy candidate for Dravet syndrome. In the U.S., the company intends to launch the ENDEAVOR trial (NCT05419492) in the first half of the year, enrolling approximately 22 infants and young children aged 6 months to nearly 3 years old. Study sites in California and Texas will be recruiting eligible participants.

 

Dravet Syndrome Overview

Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare and severe form of epilepsy that begins in infancy or early childhood. It is characterized by prolonged and frequent seizures, often starting with fever-related seizures (febrile seizures) that may evolve into other types of seizures, including myoclonic seizures, tonic-clonic seizures (grand mal seizures), and absence seizures.

 

Get a Free Sample PDF Report to know more about Dravet Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dravet-syndrome-pipeline-insight

 

Emerging Dravet Syndrome Drugs Under Different Phases of Clinical Development Include:

  • TAK-935 (soticlestat): Takeda

  • BELVIQ (lorcaserin): Eisai

  • STK-001: Stoke Therapeurtics

  • EPX-100: EpyGenix Therapeutics

  • ganaxolone: Marinus Pharmaceuticals

  • EPX-100 (Clemizole HCl): Epygenix

  • STK-001: Stoke Therapeutics, Inc

  • ZX008 (Fenfluramine Hydrochloride): Zogenix International Ltd, Inc.

  • Soticlestat: Takeda

  • GWP42003-P: Jazz Pharmaceuticals

  • Soticlestat: Ovid Therapeutics Inc.

  • LP352: Longboard Pharmaceuticals

 

Dravet Syndrome Route of Administration

Dravet Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Dravet Syndrome Molecule Type

Dravet Syndrome Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Dravet Syndrome Pipeline Therapeutics Assessment

  • Dravet Syndrome Assessment by Product Type

  • Dravet Syndrome By Stage and Product Type

  • Dravet Syndrome Assessment by Route of Administration

  • Dravet Syndrome By Stage and Route of Administration

  • Dravet Syndrome Assessment by Molecule Type

  • Dravet Syndrome by Stage and Molecule Type

 

DelveInsight’s Dravet Syndrome Report covers around 16+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Dravet Syndrome product details are provided in the report. Download the Dravet Syndrome pipeline report to learn more about the emerging Dravet Syndrome therapies

 

Some of the key companies in the Dravet Syndrome Therapeutics Market include:

Key companies developing therapies for Dravet Syndrome are – GW Pharmaceuticals Ltd, Zogenix Inc, Stoke Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Supernus Pharmaceuticals Inc, and others.

 

Dravet Syndrome Pipeline Analysis:

The Dravet Syndrome pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dravet Syndrome with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dravet Syndrome Treatment.

  • Dravet Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Dravet Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dravet Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Dravet Syndrome drugs and therapies

 

Dravet Syndrome Pipeline Market Strengths

  • The researchers are undergoing advancement in already approved drugs by providing an alternative means of delivering the drug.

  • A broader awareness among health care providers and the public for better treatments helps to improve care and outcomes.

  • Development of long-acting injectable Antipsychotics.

 

Dravet Syndrome Pipeline Market Opportunities

  • Demands of advanced therapeutics and presence of significant number of pipeline drugs.

  • There is growing evidence that patients with a dual diagnosis does not respond well to conventional psychiatric treatment, creating demand for a new approach from a different perspective.

  • Because of the increase in the side effects and less efficacious drug, the demand for specific therapy also increases.

 

Scope of Dravet Syndrome Pipeline Drug Insight    

  • Coverage: Global

  • Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others

  • Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others

  • Dravet Syndrome Therapeutic Assessment: Dravet Syndrome current marketed and Dravet Syndrome emerging therapies

  • Dravet Syndrome Market Dynamics: Dravet Syndrome market drivers and Dravet Syndrome market barriers 

 

Request for Sample PDF Report for Dravet Syndrome Pipeline Assessment and clinical trials

 

Table of Contents

1. Dravet Syndrome Report Introduction

2. Dravet Syndrome Executive Summary

3. Dravet Syndrome Overview

4. Dravet Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Dravet Syndrome Pipeline Therapeutics

6. Dravet Syndrome Late Stage Products (Phase II/III)

7. Dravet Syndrome Mid Stage Products (Phase II)

8. Dravet Syndrome Early Stage Products (Phase I)

9. Dravet Syndrome Preclinical Stage Products

10. Dravet Syndrome Therapeutics Assessment

11. Dravet Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dravet Syndrome Key Companies

14. Dravet Syndrome Key Products

15. Dravet Syndrome Unmet Needs

16 . Dravet Syndrome Market Drivers and Barriers

17. Dravet Syndrome Future Perspectives and Conclusion

18. Dravet Syndrome Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/